Psyence Biomedical Ltd. Announces Receipt of Staff Delisting Determination from NasdaqPsyence Group2024-09-16T13:55:07+02:00September 14, 2024|Read More
Psyence Biomed Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative CarePsyence Group2024-09-12T08:28:18+02:00September 11, 2024|Read More
Psyence Biomed Announces the Signing of a Conditional Binding Term Sheet for the Acquisition of Psilocybin-Based Drug Developer ClairvoyantPsyence Group2024-09-09T16:53:12+02:00September 9, 2024|Read More
Psyence Biomed Announces Worldwide Exclusive Licensing Agreement with PsyLabs to Supply Nature-Derived Psilocybin to be Evaluated as a Potential Treatment for Alcohol Use Disorder (AUD) and Other Substance Use Disorders (SUDs)Psyence Group2024-09-04T15:02:32+02:00September 4, 2024|Read More
Psyence Biomed to Present at the H.C. Wainwright 26th Annual Global Investment Conference, September 9th-11th, 2024Psyence Group2024-08-30T08:26:25+02:00August 30, 2024|Read More
Optimi Health and Psyence Biomedical Sign Non-Binding Letter of Intent to Advance Global Psilocybin Drug DevelopmentPsyence Group2024-08-27T10:00:50+02:00August 13, 2024|Read More
Psyence Biomed Enters Into $25 Million Common Stock Purchase Agreement with White Lion Capital, LLCPsyence Group2024-08-27T09:55:48+02:00August 2, 2024|Read More
Psyence Biomed Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb TrialPsyence Group2024-08-27T14:01:21+02:00July 25, 2024|Read More
Psyence Biomed to Participate in the A.G.P. Virtual Healthcare Company ShowcasePsyence Group2024-08-27T09:57:50+02:00May 17, 2024|Read More
